Shineco(US:SISI) Prnewswire·2025-09-10 13:30Core Insights - Shineco Inc. has achieved a significant breakthrough in the large-scale production of high-purity, highly active free-form soybean phospholipids through its proprietary APCC-UF technology, addressing a global technical challenge in the industry [1][4]. Technology and Production - The APCC-UF technology utilizes 70–80% pure water as a solvent and fresh soybean colloid as raw material, eliminating chemical solvents and allowing for precise extraction of high-purity active phospholipids under mild conditions [3][4]. - Testing results show a total phospholipid content of 97.8%, with phosphatidylcholine (PC) content at 50.2%, and no detectable solvent or heavy metal residues, indicating superior quality compared to traditional methods [3][4]. - The technology has been validated on a thousand-ton production line, with plans to expand to a ten-thousand-ton capacity, significantly increasing yield and reducing production costs [4]. Market Impact - This advancement is expected to reshape the global active phospholipid industry, providing essential materials for mRNA vaccine delivery, liposomal drug development, and various health applications [5][6]. - The global pharmaceutical phospholipid market is projected to grow at a compound annual growth rate (CAGR) of over 15% in the next five years, indicating strong demand for Shineco's products [6]. Competitive Position - Shineco's phospholipid products are positioned to compete in both the research-grade market and emerging sectors such as pharmaceutical intermediates and high-end skincare, leveraging its cost advantages and innovative technology [6][7]. - The company's technological breakthrough is seen as a model of Chinese leadership in high-end biomanufacturing, potentially transforming its business structure and enhancing gross margins and overall valuation [5][7].